Articles related to RESEARCH & CLINICAL TRIALS

A recent study involving 20,440 older adults with kidney failure found that initiating dialysis at an eGFR below 12 mL/min/1.73 m2 resulted in a mean survival of 770 days over a 3-year period, compared to 761 days for those continuing medical management

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

The I-SPY2 trial demonstrates that novel treatment approaches can yield high pathologic complete response rates in rare histologic subtypes of high-risk breast cancer, potentially improving outcomes for these challenging cases.

Valoctocogene roxaparvovec gene therapy demonstrates long-term efficacy in reducing bleeding episodes and factor VIII use in patients with severe hemophilia A, potentially changing the treatment landscape for this condition.

Stellate ganglion block reduces vasomotor symptom frequency by 4-90% in clinical trials, offering a potential non-hormonal option for women with severe symptoms refractory to conservative care.